NASDAQ$BMRN
BioMarin Pharmaceutical Inc · Q1 2021 earnings
Q1 2021 earnings · · Investor relations
Briefing
BioMarin's financial performance decreased slightly due to lower Kuvan sales, but was offset by increased Vimizim and Palynziq revenues.
BioMarin announced its Q1 2021 financial results, with total revenues decreasing by 3% compared to Q1 2020, primarily due to lower Kuvan sales. However, Vimizim and Palynziq revenues increased. The company reaffirmed its full-year 2021 financial guidance and anticipates regulatory decisions for vosoritide and valoctocogene roxaparvovec in Europe.
- Total revenues decreased by 3% in Q1 2021 compared to Q1 2020, excluding Kuvan revenues grew by 9%.
- GAAP Net Income decreased to $17.4 million for Q1 2021, compared to $81.4 million for the same period in 2020.
- The company reaffirms its plan to submit the Marketing Authorization Application with one-year results from the Phase 3 GENEr8-1 study to the European Medicines Agency (EMA) in June 2021.
- FDA Review of Vosoritide Proceeding; PDUFA Target Action Date Extended to November 20, 2021 to Provide Time for Review of Recently Submitted 2-year Phase 3 Results
Headline financials
Revenue & EPS history
BioMarin · Revenue · Quarterly
$486M
Revenue by segment
BioMarin · $468M total across 6 segments · Q1 2021
- VIMIZIM$158M+15.5%33.9%
- NAGLAZYME$107M-6.1%22.9%
- KUVAN$70.8M—15.1%
- PALYNZIQ$54M+56.1%11.5%
- ALDURAZYME$50M-10.2%10.7%
- BRINEURA$27.3M+13.8%5.8%
Forward guidance
BioMarin reaffirmed its full-year 2021 financial guidance, taking into consideration the ongoing impact from the COVID-19 pandemic and the essential nature of its products.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q1 2021
-0.5%
Avg return
Earnings day
-0.2%
Avg return
5 days after
-0.6%
Avg return
30 days after
44%
30 / 68 earnings
Positive
+9.0%
Q3 2014
Best reaction
-10.7%
Q1 2024
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +2.4% | +0.0% | +1.2% | |
| Q4 2025 | -2.7% | -1.9% | -11.7% | |
| Q3 2025 | +1.4% | +1.7% | +5.4% | |
| Q1 2025 | -1.3% | -5.4% | -7.4% | |
| Q4 2024 | +4.8% | +8.5% | +8.6% | |
| Q3 2024 | -4.9% | -5.0% | -6.7% | |
| Q2 2024 | +3.2% | +5.3% | +6.7% | |
| Q1 2024 | -10.7% | -10.8% | -18.0% | |
| Q4 2023 | +3.0% | +2.4% | -3.9% | |
| Q3 2023 | -2.2% | -6.4% | +13.5% | |
| Q2 2023 | +1.6% | +1.1% | +7.1% | |
| Q1 2023 | -3.3% | +1.5% | -7.4% | |
| Q4 2022 | -2.4% | -0.9% | -7.7% | |
| Q3 2022 | -6.3% | -5.3% | +6.0% | |
| Q2 2022 | +7.3% | +10.4% | +3.4% | |
| Q1 2022 | +4.2% | +5.1% | +2.1% | |
| Q4 2021 | -9.4% | -8.5% | -7.4% | |
| Q3 2021 | +6.5% | +11.8% | +19.3% | |
| Q2 2021 | +0.2% | -1.2% | +6.6% | |
| Q1 2021 | -3.2% | -2.6% | -3.9% | |
| Q4 2020 | -7.1% | -6.5% | -9.4% | |
| Q3 2020 | +0.5% | -0.2% | +4.2% | |
| Q2 2020 | -1.8% | -2.8% | -37.9% | |
| Q1 2020 | -2.6% | -4.4% | +12.8% | |
| Q4 2019 | -1.3% | +3.7% | -12.6% | |
| Q3 2019 | +2.5% | +6.5% | +14.8% | |
| Q2 2019 | -1.9% | -4.2% | -5.4% | |
| Q1 2019 | -0.5% | +0.0% | +4.1% | |
| Q4 2018 | -3.1% | +1.7% | -2.9% | |
| Q3 2018 | +4.9% | -0.8% | +1.0% | |
| Q2 2018 | -1.5% | +4.7% | -1.0% | |
| Q1 2018 | +1.7% | +2.9% | +14.0% | |
| Q4 2017 | -1.4% | -1.4% | -6.4% | |
| Q3 2017 | -1.9% | -3.2% | -2.5% | |
| Q2 2017 | +1.7% | +1.2% | +3.0% | |
| Q1 2017 | -1.8% | -5.0% | -5.5% | |
| Q4 2016 | -2.5% | +4.6% | -2.7% | |
| Q3 2016 | -0.8% | +1.2% | +8.9% | |
| Q2 2016 | -2.5% | -6.2% | -5.6% | |
| Q1 2016 | -3.5% | — | — | |
| Q4 2015 | +5.0% | — | — | |
| Q3 2015 | +2.9% | — | — | |
| Q2 2015 | -1.7% | — | — | |
| Q1 2015 | +0.6% | — | — | |
| Q4 2014 | +2.7% | — | — | |
| Q3 2014 | +9.0% | — | — | |
| Q2 2014 | +1.3% | — | — | |
| Q1 2014 | -0.9% | — | — | |
| Q4 2013 | +1.3% | — | — | |
| Q3 2013 | -2.1% | — | — | |
| Q2 2013 | +1.0% | — | — | |
| Q1 2013 | +1.4% | — | — | |
| Q4 2012 | +1.7% | — | — | |
| Q3 2012 | -4.7% | — | — | |
| Q2 2012 | -5.2% | — | — | |
| Q1 2012 | -1.4% | — | — | |
| Q4 2011 | -0.0% | — | — | |
| Q3 2011 | -7.2% | — | — | |
| Q2 2011 | -6.5% | — | — | |
| Q4 2010 | +3.2% | — | — | |
| Q1 2011 | +1.8% | — | — | |
| Q4 2008 | +0.3% | — | — | |
| Q3 2010 | +4.0% | — | — | |
| Q3 2009 | +4.0% | — | — | |
| Q4 2009 | -0.6% | — | — | |
| Q2 2009 | -0.6% | — | — | |
| Q2 2010 | -0.6% | — | — | |
| Q1 2010 | -8.0% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro